SSTR2 activity can be modulated by the somatostatin analog octreotide, which is used clinically to control the growth of and secretion of hormones from neuroendocrine tumors, such as insulinomas and growth hormone-secreting pituitary tumors.59 Furthermore, octreotide acutely increases the expression of markers of bone resorption and formation in healthy subjects.60 The gene discussed is GH1; the disease is pituitary tumor.